Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00099437 · OUTCOME

Overall Survival (OS)

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. · Source last updated 2026-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Time (in months)
Interval / dispersion
Full Range
Time frame
Overall Survival is equivalent to time to death. For this endpoint, all deaths occurring for study duration (48 months)

What was measured

Median time (in months) from randomisation until death (from any cause) (analysis at 50% deaths )

Analysis population: All patients with measurable disease at baseline.

Groups in this outcome

Fulvestrant 250 mg

Fulvestrant 250 mg Intramuscular Injection every 28 days

Fulvestrant 500 mg

Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fulvestrant 250 mg374
Fulvestrant 500 mg362

Reported measurements

Source class 1
Values in Time (in months) · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Fulvestrant 250 mg22.8Not reported0.2NANot Applicable - not all participants had an event at time of analysis, max time censored
Fulvestrant 500 mg25.1Not reported0.1NANot Applicable - not all participants had an event at time of analysis, max time censored
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not Applicable - not all participants had an event at time of analysis, max time censored
        group Id
        OG000
        lower Limit
        0.2
        upper Limit
        NA
        value
        22.8
      2. comment
        Not Applicable - not all participants had an event at time of analysis, max time censored
        group Id
        OG001
        lower Limit
        0.1
        upper Limit
        NA
        value
        25.1
denoms
  1. counts
    1. group Id
      OG000
      value
      374
    2. group Id
      OG001
      value
      362
    units
    Participants
description
Median time (in months) from randomisation until death (from any cause) (analysis at 50% deaths )
dispersion Type
Full Range
groups
  1. description
    Fulvestrant 250 mg Intramuscular Injection every 28 days
    id
    OG000
    title
    Fulvestrant 250 mg
  2. description
    Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14
    id
    OG001
    title
    Fulvestrant 500 mg
param Type
MEDIAN
population Description
All patients with measurable disease at baseline.
reporting Status
POSTED
time Frame
Overall Survival is equivalent to time to death. For this endpoint, all deaths occurring for study duration (48 months)
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Time (in months)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice